CARE Equity Research has assigned fundamental grade of 3/5, indicating good fundamentals for Elder Pharmaceuticals (EPL).
The grading draws its strength from the company’s presence in niche therapeutic segments across women’s healthcare, nutraceuticals, pain management and anti-infectives, all of which are growing at a high growth rate with strong brands both owned and in-licensed. EPL also has a healthy mix of formulations and Active Pharmaceutical Ingredients (APIs) and has developed eight new APIs in the past using its internal R&D.
The company has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.
